Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data
A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ -- Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy...
XtalPi Submits U.S. FDA IND Application for KQTD-126, a Potential First-in-Class, Gut-Restricted Pan-TRK Inhibitor for Chronic Intestinal Pain
This milestone marks the first IND submission from XtalPi's proprietary pipeline, recently unveiled in its interim results, validating the company's AI and robotics-driven drug discovery platform and its transition to a clinical-stage organization. Preclinical data demonstrate sub-nanomolar potency (< 1 nM) alongside a gut-to-blood exposure ratio exceeding 1,000:1, confining pharmacological...
Strategic Collaboration | Sanyou Bio and NovoCodex Partner to Co-Develop Innovative Dual-Payload ADCs
SHANGHAI and SHAOXING, China, Sept. 24, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd. ("Sanyou Bio") and NovoCodex Biopharmaceuticals Co., Ltd. ("NovoCodex") jointly announced that the two companies have formally entered into a strategic collaboration agreement. The partnership will focus on the joint development of innovative antibody-drug conjugates (ADCs), leveraging Sanyou Bio's strengths in innovative ADC discovery powered by...
MSF Shares Experience in Delivering Cancer Care to Women in Humanitarian Crises at World Cancer Congress 2026
HONG KONG, Sept. 24, 2026 /PRNewswire/ -- Speaking for the first time at the World Cancer Congress in Hong Kong this week, Médecins Sans Frontières/Doctors Without Borders (MSF), an international medical humanitarian organisation, will share its experiences from its cancer programmes in Mali and Malawi, highlighting that cancer care is possible in resource-limited settings, but urgent action is needed...
From diagnosis to treatment, ZEISS introduces innovations across ZEISS Retina Workflow at EURETINA 2026
ZEISS Medical Technology advances its ZEISS Retina Workflow with digital and surgical enhancements, and new imaging technologies, including: Diagnostics: ZEISS expands its retinal imaging portfolio with the new ZEISS ALTA DUO 300, combining OCT and fundus imaging in a single device. Visualization: New HMDmd CR3, head-mounted 3D digital display technology, connects with ZEISS ARTEVO...
Earendil Labs Announces Research Collaboration with Genentech to Discover and Develop Therapeutic Bispecific Antibodies in Oncology
WILMINGTON, Del., Sept. 24, 2026 /PRNewswire/ -- Earendil Labs, an AI-powered biotechnology company advancing next-generation biologics, today announced a research collaboration with Genentech, a member of the Roche Group, to discover and develop multiple therapeutic bispecific antibody programs in oncology. Under the collaboration, Earendil Labs will lead antibody discovery and research through the early clinical development stage for...
Uxin Reports Unaudited Financial Results for the Quarter Ended June 30, 2026
BEIJING, Sept. 24, 2026 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company") (Nasdaq: UXIN), China's leading used car retailer, today announced its unaudited financial results for the quarter ended June 30, 2026. Highlights for the Quarter Ended June 30, 2026 Transaction volume was 21,899 units for the three months ended June 30, 2026, representing an increase of...
Taiwanese Team Highlights Precision Indoxyl Sulfate Testing for Early CKD Management in Japan
TOKYO, Sept. 24, 2026 /PRNewswire/ -- Chronic kidney disease (CKD) is often called a "silent disease" because its early stages may cause few noticeable symptoms. Taiwan has one of the world's highest burdens of end-stage renal disease requiring hemodialysis. Approximately 1.5 million Taiwanese adults are estimated to have Stage 3–5 CKD, yet fewer than 10% of patients are...
After the Weight Comes Off: Treating GLP-1-Related Skin Laxity with Sofwave
SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Across cosmetic and dermatology clinics, a new patient profile is becoming increasingly familiar. Someone who has lost a significant amount of weight on a GLP-1 medication and is thrilled with the overall result but is now booking a consultation for something the scale never showed them... loose, deflated looking skin. This shift is...
NCCN Models How to Tailor Cancer Care for Different Regions During 2026 World Cancer Congress
National Cancer Control Plans can and should include regionally appropriate guidelines according to abstracts presented by the National Comprehensive Cancer Network during global event hosted by the Union of International Cancer Control. PLYMOUTH MEETING, Pa. and HONG KONG, Sept. 24, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading...
